Intermittent Claudication
Welcome,         Profile    Billing    Logout  
 15 Companies   14 Products   14 Products   17 Mechanisms of Action   0 Trials   91 News 


12»
  • ||||||||||  Trial completion, Trial primary completion date:  Home-based vs. Supervised Exercise for People With Claudication (clinicaltrials.gov) -  Feb 27, 2018   
    P=N/A,  N=135, Completed, 
    Trial completion date: Dec 2016 --> Feb 2016 | Trial primary completion date: Dec 2016 --> Feb 2016 Recruiting --> Completed | Trial primary completion date: Jul 2011 --> Sep 2016
  • ||||||||||  Trial completion, Trial initiation date, Trial primary completion date:  WITH-SAS: Obstructive Sleep Apnoea in Patients With Intermittent Claudication (clinicaltrials.gov) -  Nov 1, 2017   
    P=N/A,  N=140, Completed, 
    N=400 --> 240 | Trial primary completion date: Nov 2013 --> May 2016 Recruiting --> Completed | Initiation date: Feb 2013 --> May 2013 | Trial primary completion date: May 2016 --> Oct 2017
  • ||||||||||  emiplacel (PLX-PAD) - Pluri, Charite / University of Medicine Berlin
    Enrollment closed, Trial primary completion date:  Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC) (clinicaltrials.gov) -  Jan 23, 2017   
    P2,  N=172, Active, not recruiting, 
    Completed --> Terminated Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Apr 2018
  • ||||||||||  Trial completion, Enrollment change, HEOR:  Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD) (clinicaltrials.gov) -  Dec 16, 2016   
    P=N/A,  N=323, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Apr 2018 Active, not recruiting --> Completed | N=1100 --> 323
  • ||||||||||  zibotentan (ZD4054) / AstraZeneca
    Trial completion, Enrollment change, Trial primary completion date:  Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication (clinicaltrials.gov) -  Aug 2, 2016   
    P2,  N=31, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=44 --> 31 | Trial primary completion date: Jun 2015 --> Jun 2016
  • ||||||||||  emiplacel (PLX-PAD) - Pluri, Charite / University of Medicine Berlin
    Trial primary completion date:  Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC) (clinicaltrials.gov) -  May 25, 2016   
    P2,  N=150, Recruiting, 
    Recruiting --> Completed | N=44 --> 31 | Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Apr 2016 --> Jul 2017
  • ||||||||||  emiplacel (PLX-PAD) - Pluri, Charite / University of Medicine Berlin
    Trial primary completion date:  Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC) (clinicaltrials.gov) -  Feb 3, 2016   
    P2,  N=150, Recruiting, 
    N=80 --> 2 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Dec 2014; The trial has been terminated due to difficulties with recruitment. Trial primary completion date: Dec 2015 --> Apr 2016
  • ||||||||||  ALD-301 / Nuo Therapeutics
    Enrollment closed:  Patients With Intermittent Claudication Injected With ALDH Bright Cells (clinicaltrials.gov) -  Jan 15, 2016   
    P2,  N=82, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Apr 2016 Recruiting --> Active, not recruiting
  • ||||||||||  ALD-301 / Nuo Therapeutics
    Trial primary completion date:  Patients With Intermittent Claudication Injected With ALDH Bright Cells (clinicaltrials.gov) -  Nov 10, 2015   
    P2,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Aug 2016
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Objective Evaluation of Proximal Ischemia (clinicaltrials.gov) -  Jul 17, 2015   
    P=N/A,  N=165, Completed, 
    Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed
  • ||||||||||  Trial completion, Surgery:  Neurogenic Intermittent Claudication Evaluation Study (clinicaltrials.gov) -  Jun 6, 2015   
    P4,  N=128, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  COAST: Condition of Approval Study (clinicaltrials.gov) -  May 19, 2015   
    P4,  N=176, Terminated, 
    Active, not recruiting --> Completed N=240 --> 176 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Feb 2015; Due to Medtronic's voluntary withdrawal of PMA P040001 for X-STOP systems; post-approval study costs outweighed business benefits for marketing X-STOP in US.
  • ||||||||||  Enrollment closed:  COAST: Condition of Approval Study (clinicaltrials.gov) -  Mar 26, 2015   
    P4,  N=240, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  ramipril / Generic mfg.
    Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, HEOR, Cost effectiveness:  Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants (clinicaltrials.gov) -  Dec 19, 2014   
    P4,  N=33, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Dec 2014 Not yet recruiting --> Completed | N=78 --> 33 | Initiation date: Feb 2010 --> Dec 2010 | Trial primary completion date: Apr 2011 --> Dec 2012
  • ||||||||||  ALD-301 / Nuo Therapeutics
    Trial primary completion date:  Patients With Intermittent Claudication Injected With ALDH Bright Cells (clinicaltrials.gov) -  Nov 4, 2014   
    P2,  N=80, Recruiting, 
    Not yet recruiting --> Completed | N=78 --> 33 | Initiation date: Feb 2010 --> Dec 2010 | Trial primary completion date: Apr 2011 --> Dec 2012 Trial primary completion date: Nov 2014 --> Jan 2016
  • ||||||||||  atorvastatin / Generic mfg., pioglitazone / Generic mfg.
    Enrollment change:  ARREST PAD (Peripheral Arterial Disease) (clinicaltrials.gov) -  Sep 30, 2014   
    P2/3,  N=76, Completed, 
    N=100 --> 0 | Not yet recruiting --> Withdrawn N=113 --> 76
  • ||||||||||  Trial primary completion date:  COAST: Condition of Approval Study (clinicaltrials.gov) -  Sep 19, 2014   
    P4,  N=240, Recruiting, 
    Recruiting --> Completed Trial primary completion date: Jul 2019 --> Jul 2022
  • ||||||||||  ticagrelor / Generic mfg., clopidogrel / Generic mfg.
    Trial initiation date, Trial primary completion date:  Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients (clinicaltrials.gov) -  Aug 8, 2014   
    P4,  N=100, Not yet recruiting, 
    Trial primary completion date: Jul 2019 --> Jul 2022 Initiation date: Sep 2014 --> Dec 2014 | Trial primary completion date: Oct 2015 --> Feb 2016
  • ||||||||||  ticagrelor / Generic mfg., clopidogrel / Generic mfg.
    Trial primary completion date:  Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients (clinicaltrials.gov) -  Jun 19, 2014   
    P4,  N=100, Not yet recruiting, 
    Initiation date: Sep 2014 --> Dec 2014 | Trial primary completion date: Oct 2015 --> Feb 2016 Trial primary completion date: Jun 2015 --> Oct 2015
  • ||||||||||  ticagrelor / Generic mfg., clopidogrel / Generic mfg.
    Trial initiation date, Trial primary completion date:  Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients (clinicaltrials.gov) -  Jun 19, 2014   
    P4,  N=100, Not yet recruiting, 
    Trial primary completion date: Jun 2015 --> Oct 2015 Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: Jun 2015 --> Oct 2015
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Exercise Training for Patients With Poor Leg Circulation (clinicaltrials.gov) -  Feb 22, 2014   
    P=N/A,  N=50, Completed, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Completed